Thiazolidinedione PPARγ agonists (troglitazone and rosiglitazone) were previously shown to promote colon tumor formation in C57BL/6J-APC min /+ mice, a model for human familial adenomatous polyposis. This study was conducted to determine if another thiazolidinedione PPARγ agonist, pioglitazone, and a PPARγ agonist structurally unrelated to the thiazolidinedione family, NID525, (a tetrazole-substituted phenoxymethylquinolone), would also promote colon tumors in this mouse model. Mice were treated in-feed with the thiazolidinediones troglitazone (150 mg/kg/day), rosiglitazone (20 mg/kg/day), or pioglitazone (150 mg/kg/day), or with NID525 (150 mg/kg/day) for 8 weeks. An increased incidence in colon tumors compared to controls was observed for all of the thiazolidinedione-treated groups as well as the NID525-treated group. These results indicate that the tumor-promoting effect of PPARγ agonists in the colon of C57BL/6J-APC min /+ mice is likely related to the pharmacological activity of this group of drugs and not the thiazolidinedione structure.
INTRODUCTION
Peroxisome proliferator-activated receptor gamma (PPARγ ) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and has been shown to play a role in the regulation of lipid metabolism (Willson et al., 1996) . Although early studies suggested that adipose tissue had the highest levels of PPARγ , recent studies indicate that PPARγ is also highly expressed in other tissues including normal human and mouse colon, azoxymethane-induced rat colon tumors, and human colonic adenocarcinomas (DuBois et al., 1998; Mansen et al., 1996; Sarraf et al., 1998) .
The thiazolidinediones are a class of drugs being utilized for the treatment of non-insulin-dependent diabetes, and it has been demonstrated that they are high affinity ligands for PPARγ (Lehmann et al., 1995) . Thiazolidinediones enhance glucose utilization without stimulating insulin secretion, and effectively lower serum glucose levels (Willson et al., 1996) . Two thiazolidinedione PPARγ agonists, troglitazone and rosiglitazone, were previously reported to promote the development of colon tumors in C57BL/6J-APC min /+ mice (Lefebvre et al., 1998; Saez et al., 1998) . This model is an inbred mouse line with a nonsense mutation in the adenomatous polyposis coli (APC) tumor suppresser gene that makes them susceptible to intestinal neoplasia (Moser et al., 1990; Su et al., 1992) .
The purpose of this study was to determine if another thiazolidinedione PPARγ agonist, pioglitazone, and a PPARγ agonist structurally unrelated to the thiazolidinedione family, NID525, could also promote colon tumors in the C57BL/6J-APC min /+ mouse model. NID525 is a tetrazole-substituted phenoxymethylquinolone that was initially developed as an LTD 4 antagonist (Bonnefoi et al., 1995) , but was later found to also be a potent PPARγ agonist (Jayyosi et al., 1999) . In a pharmacology model for diabetes (i.e., db/db mouse model), NID525 was found to be more potent than troglitazone, but less potent than rosiglitazone (results not shown).
In the present study, the colon tumor promoting activity of NID525 and pioglitazone was evaluated in conjunction with troglitazone and rosiglitazone.
METHODS

Chemicals
NID525, troglitazone, rosiglitazone and pioglitazone were synthesized by Rhône-Poulenc Rorer Ltd., Dagenham, Essex, UK (now Aventis). Compound purity by HPLC was 99.4% for NID525, 98% for troglitazone, 96% for pioglitazone, and 95% for rosiglitazone. The chemical structures for the four compounds tested are given in Fig. 1 .
Animals
Male C57BL/6J-APC min /+ mice, 6-7 weeks of age and weighing 17.9-22.6 g at study initiation, were supplied by Jackson Laboratory, Bar Harbor, Maine. The mice were assigned to dosage groups by body weight-balanced randomization.
Mice were handled and maintained in accordance with the requirements of the Laboratory Animal Welfare Act. The study was conducted in facilities accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International (AAALAC) under federal guidelines for the care and use of laboratory animals (Institute of Laboratory Animal Resources, National Research Council, 1996) .
The mice were housed individually during the study in suspended stainless steel wire-mesh cages and maintained under 
Experimental Design and Procedures
Mice were divided into 5 groups of 15 animals/group. Control mice received Certified Purina Rodent Chow #5002 ad libitum, while treated mice received PPARγ agonists in-feed ad libitum to achieve a daily dose of 150 mg/kg for NID525, troglitazone and pioglitazone, or 20 mg/kg for rosiglitazone. Doses for NID525, troglitazone and rosiglitazone was selected based on an in-feed study using C57BL/6J-db/db mice where it was shown that NID525 and troglitazone had approximately similar potency in lowering plasma glucose, free fatty acid, triglyceride, and insulin levels, while rosiglitazone was approximately 10-fold more potent (unpublished data). The pioglitazone dose was chosen based on results of a PPARγ transactivation assay where the EC 50 for pioglitazone was determined to be similar to NID525 (unpublished data). Doses for troglitazone and rosiglitazone were the same as those previously reported in the literature to induce colon tumors in male C57BL/6J-APC min /+ mice (Lefebvre et al., 1998) .
The treatment period for all groups was 8 weeks. Body weights and food consumption were determined weekly; these data were used to adjust the amounts of test material that were mixed with feed in order to achieve the desired dosages.
Animals were examined daily for mortality and clinical signs. All mice surviving to the end of treatment were anesthetized with pentobarbital and euthanatized by exsanguination from the abdominal aorta. Following euthanasia, the entire intestinal tract from each mouse was immediately removed and divided into 5 sections from the duodenum to the rectum: 2 sections of equal length from the proximal half of the small intestine (sections 1&2), 2 sections of equal length from the distal half of the small intestine (sections 3&4), and 1 section of the large intestine that included all of the cecum, colon, and rectum (section 5). The intestinal sections were opened, and a dissecting microscope (magnification 20X) was used to identify nodules/masses in each section. A calibrated reticle in an eyepiece of the dissecting scope was used to measure the diameter of each nodule or mass at its maximum dimension. Lesions less than 0.5 mm in diameter were not enumerated. All lesion counts and measurements were performed by one evaluator blinded to treatment group assignments. After the count/size measurements were obtained, the entire segment of each intestinal section was pinned open on corkboard and fixed in 10% neutral buffered formalin.
All nodules/masses in section 5 (large intestine) from all mice euthanatized at study termination were processed, sectioned, stained with hematoxylin and eosin, and examined microscopically in order to classify and confirm them as a neoplasm. Classification was based on standard nomenclature (Whitely et al., 1996) . Any lesion in section 5 that was not confirmed microscopically as a neoplasm was excluded from statistical analysis. All nodules/masses in the proximal and distal small intestine were considered to be tumors for purposes of statistical analysis and were not subjected to microscopic evaluation.
Statistics
Changes at all intervals in weekly body weight and food consumption were analyzed using a pair-wise comparison where each treated group was compared to control ( p ≤ 0.05).
Tumor numbers were analyzed based on their location in the following segments of the intestinal tract: proximal small TOXICOLOGIC PATHOLOGY intestine (sections 1&2), distal small intestine (sections 3&4), and large intestine (section 5). For each region, the number of tumors per mouse in each of the 4 treated groups was compared to that of the control group using the Mann-Whitney test ( p ≤ 0.05). Analyses were 2-sided. The average tumor size per mouse was also determined for each segment of intestine; however, mice without tumors were excluded from calculation of the mean value for this parameter. Therefore, it was not appropriate to perform statistical analysis on these data.
RESULTS
Mortality:
One mouse from the rosiglitazone-treated group was euthanatized due to a prolapsed rectum after 6 weeks of dosing. All tumor data for this animal were excluded from analysis.
Body Weight and Food Consumption: The group mean body weight values are presented in Fig. 2 . Mice treated with rosiglitazone and pioglitazone tended to have slightly higher body weights than mice in the other groups throughout most of the study period.
The group mean food consumption values are presented in Fig. 3 . Small, statistically significant increases in food consumption compared to controls were observed in the rosiglitazone and troglitazone groups on days 8 and/or 36.
Tumor Counts and Size
For those mice euthanatized at study termination, all mice in all groups had at least one tumor in each segment of proximal and distal small intestine. The numbers of mice with at least one tumor in the large intestine were 9/15, 15/15, 14/14, 14/15, and 15/15 for the control, NID525, rosiglitazone, troglitazone, and pioglitazone groups, respectively.
The mean number of tumors per mouse in each segment of intestine for each group is shown in Fig. 4 . There was a significant increase in the average number of tumors in the large intestine per mouse for all treatment groups compared to the control group. There were no meaningful differences between the treated groups and the control group for the average number of tumors per mouse in the proximal and distal small intestine.
For those mice having tumors, the average tumor size per mouse in each segment of intestine for each group is given in Fig. 5 . The average size per mouse for tumors in the large intestine was smaller for all of the treated groups compared to the control group (mice without tumors were excluded). For the proximal and distal small intestine, there were no meaningful differences in average tumor size per mouse between any of the treated groups and the control group.
Tumor Morphology: The morphologic features for tumors of the large intestine in all groups were similar. All tumors were classified as adenomas with the exception of 1 adenocarcinoma in a troglitazone-treated mouse. Adenomas usually had either a polypoid or crateriform appearance with compression of adjacent tissue, and were composed of irregular glands lined by dysplastic, basophilic epithelial cells that were sometimes multiple layers thick (Fig. 6 ). Mitotic figures were common. For the 1 adenocarcinoma that was noted, there was local invasion of neoplastic cells into the underlying lamina propria/submucosa (Fig. 7) .
In addition to tumors, hyperplastic foci were also noted in the mucosa of the large intestine, and their incidence appeared slightly increased in mice treated with rosiglitazone, troglitazone and pioglitazone compared to the control group. Hyperplastic foci were characterized by thickened areas of mucosa containing elongated crypts that were lined by either normal or dysplastic epithelium. The normal mucosal architecture in the hyperplastic foci was preserved, and there was no compression of adjacent tissue.
The total number of each type of proliferative lesion in the large intestine for each group (combining each type of proliferative lesion from all mice within the group) is given in Table 1 . Vol. 32, No. 1, 2004 MOUSE COLON TUMORS AND PPARγ AGONISTS 61 FIGURE 4 .-Average number of tumors per mouse in the proximal small intestine, distal small intestine, and large intestine for control mice and mice treated with NID525, rosiglitazone, troglitazone, or pioglitazone (mean ± SEM). Asterisk indicates significantly different than control, p ≤ 0.05, Mann-Whitney test.
DISCUSSION
In this study, we confirmed that the thiazolidinediones, troglitazone, and rosiglitazone, were capable of promoting colon tumors in C57BL/6J-APC min /+ mice as was previously a Combines each type of proliferative lesion from all mice within the group.
FIGURE 5.-Average tumor size per mouse (excluding mice without tumors) in the proximal small intestine, distal small intestine, and large intestine for control mice and mice treated with NID525, rosiglitazone, troglitazone, or pioglitazone (mean ± SEM).
reported. In addition, it was demonstrated that another thiazolidinedione, pioglitazone, had a similar effect on promoting colon tumors, as did a PPARγ agonist that was structurally unrelated to the thiazolidinediones, NID525.
Activation of PPARγ can inhibit growth and/or regulate terminal differentiation in a variety of tissues or cell types including adipocytes (Brun and Speigelman, 1997) , human breast and prostate cancers (Kubota et al., 1998; Mueller et al., 1998) , and monocytes/macrophages . Troglitazone was shown to inhibit the growth of human colon cancer cell lines in culture or when transplanted into nude mice, and modulate differentiation of colon cancer cell lines to a less malignant state (DuBois et al., 1998; Kitamura et al., 1999) . These results suggest a protective or beneficial role for PPARγ activation in colon tumorogenesis. Recently, "loss-of-function" somatic mutations in the TOXICOLOGIC PATHOLOGY PPARγ gene have been identified in tumors from patients with primary sporadic colorectal carcinoma (Sarraf et al., 1999) . Such mutations could conceivably cause the antitumor functions of PPARγ to be lost, and would favor tumor development.
The tumor promoting activity of PPARγ agonists in our study and other studies using C57BL/6J-APC min /+ mice is inconsistent with the anti-tumor activity described previously. The mechanism(s) by which PPARγ may contribute to colon tumor promotion are unknown, but it appears that a certain genetic predisposition may be necessary before this promotional effect can be exerted (Lefebvre et al., 1998) . Mice that are heterozygous for APC min have a nonsense mutation of the APC gene that is autosomal dominant, and they are a model for the human genetic disease known as familial adenomatous polyposis (FAP) (Moser et al., 1990; Su et al., 1992) . The APC gene is also mutated in patients with FAP, and affected individuals develop numerous benign colorectal tumors during their lifetime, some of which may progress to cancer (Su et al., 1992) .
It has been suggested that one way in which PPARγ activation may promote the development of colon tumors is by leading to increased expression of β catenin protein (Lefebvre et al., 1998) . This protein activates other factors that control transcription of target genes associated with colon tumorogenesis. Alternately, β catenin protein may also regulate cellcell interactions important for tumor growth and metastasis.
The number of tumors per mouse noted in the small intestine for all groups, including controls, in this study was greater than the number previously reported in the literature for C57BL/6J-APC min /+ mice (Lefebvre et al., 1998; Moser et al., 1990) . Possible explanations for this discrepancy include diet and technical variations between laboratories (e.g., differences in magnification at which the tumor counts were performed). An association between diet and intestinal tumor formation has been recognized for several years, especially in regards to dietary fat and fiber content. Interestingly, polyunsaturated fatty acids have been shown to be natural ligands for PPARγ , and it has been suggested that diets high in polyunsaturated fats might be expected to influence PPARγ activation (Keller and Wahli, 1993) . Although dietary fiber is generally thought to exert a protective effect against colon cancer, there is also evidence that some types of fiber may promote colon tumorogenesis (Jacobs and Lupton, 1986 ). Recently, it was shown that C57BL/6J-APC min /+ mice fed low-fat, high-fiber diets had fewer small bowel tumors than Vol. 32, No. 1, 2004 MOUSE COLON TUMORS AND PPARγ AGONISTS 63 those fed a high-fat diet with no fiber, although these factors had no effect on the number of large bowel tumors (Yu et al., 2001) . Based upon these results, it is possible that differences in diet between laboratories were responsible for the higher numbers of small intestinal tumors that were observed in our study compared to those previously reported, however, as stated above, technical variations in conducting the studies may also have contributed to this observation. The average tumor size per mouse in the large intestine was smaller for all of the PPARγ agonist treated groups as compared to the control group. The smaller average tumor size in treated mice was likely the result of tumor promotion occurring throughout the treatment period. As a result, several of the tumors in the treated mice at study termination were at an earlier stage of development (and therefore smaller) than those of the control group.
The group mean body weights for mice treated with rosiglitazone or pioglitazone tended to be slightly higher than that of the controls throughout the majority of the study period. This finding was likely related to the effects of PPARγ agonists on regulation of lipid metabolism and promotion of adipocyte differentiation leading to increased fat deposition (Brun and Speigelman, 1997) .
In conclusion, the in-feed administration of thiazolidinediones or a structurally unrelated PPARγ agonist (NID525) to C57BL/6J-APC min /+ mice resulted in increased numbers of tumors in the large intestine compared to the control group. These results are in agreement with previous studies in C57BL/6J-APC min /+ mice that have shown a tumor promoting effect for PPARγ agonists in this murine model for colorectal neoplasia.
